LSL Pharma (TSXV: LSL) has announced that the FDA has certified the ophthalmic ointment manufacturing operations of its subsidiary, Steri-Med Pharma, clearing the company to commercialize ophthalmic ointment products in the U.S.
The certification follows a successful FDA inspection of Steri-Med’s facility, confirming full compliance with current Good Manufacturing Practices. According to LSL, this regulatory milestone significantly strengthens its competitive positioning, enhances future revenue diversification, and establishes a clear pathway for sustainable growth and long-term value creation for shareholders.
In a statement, François Roberge, president and CEO of LSL, commented, “Obtaining FDA certification is a major achievement for LSL Pharma and a strong validation of the quality of our operations, manufacturing expertise, and our team’s commitment to the highest regulatory standards. This approval provides us with direct access to the U.S. market, which offers strong long-term fundamentals, and positions the company to pursue future growth through new partnerships and contract manufacturing opportunities in the U.S.”
